<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846647</url>
  </required_header>
  <id_info>
    <org_study_id>RNI 2021 BOUVIER</org_study_id>
    <secondary_id>2021-A00284-37</secondary_id>
    <nct_id>NCT04846647</nct_id>
  </id_info>
  <brief_title>Study of the Inappropriate Secretion of FGF23 in Patients Followed in Hospital in a Context of Hypophosphatemia</brief_title>
  <acronym>IFEH</acronym>
  <official_title>Study of the Inappropriate Secretion of FGF23 in Patients Followed in Hospital in a Context of Hypophosphatemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DiaSorin ; Saluggia, Italia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The discovery of FGF23, the missing link in the long researched and finally found phosphate&#xD;
      metabolism, marked a turning point in the understanding and physiopathology of specific&#xD;
      hypophosphatemia. By inhibiting the renal reabsorption of phosphate and the production of&#xD;
      calcitriol, FGF23 behaves like a hypophosphatemia hormone.&#xD;
&#xD;
      Hypersecretion of FGF23 can occur in the case of genetic abnormalities (X-linked&#xD;
      hypophosphatemic vitamin-resistant rickets, recessive or dominant hypophosphatemic rickets,&#xD;
      McCune-Albright syndrome ...) or acquired abnormalities (oncogenic osteomalacia). Oncogenic&#xD;
      osteomalacia can be induced by hyperproduction of FGF23 by benign tumours of mesenchymal&#xD;
      origin. But more recently, several cases of malignant tumours secreting FGF23 have also been&#xD;
      described (prostate, colon, breast, ovarian and lung cancers, pulmonary carcinoma, etc.)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, even if the incidence of FGF23-secreting tumours seems rare, no precise&#xD;
      bibliographical data is available in the scientific literature. Future studies will have to&#xD;
      address this issue in order not to underestimate the frequency of this complication.&#xD;
&#xD;
      In this context, investigators would like to study the incidence of inappropriate FGF23&#xD;
      increase from a collection of biological samples carried out on 500 patients treated at the&#xD;
      Clermont-Ferrand University Hospital for hypophosphatemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the frequency of blood levels of FGF23 unsuitable for hypophosphatemia</measure>
    <time_frame>day 0</time_frame>
    <description>Assessing the presence of a blood level of FGF23 considered unsuitable for hypophosphatemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigate the relationship between blood levels of FGF23 and other biochemical parameters in hospital patients with hypophosphatemia..</measure>
    <time_frame>Day 1</time_frame>
    <description>Description: Measure blood levels of FGF23 in absolute value and other biochemical parameters (phosphatemia, phosphaturia, PTH, vitamin D ...)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the relationship between blood levels of FGF23 and other biochemical parameters in hospital patients with hypophosphatemia.</measure>
    <time_frame>day 1</time_frame>
    <description>Measure blood levels of FGF23 in absolute value and other biochemical parameters (phosphatemia, phosphaturia, PTH, vitamin D ...).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hypophosphatemia Without Immediate Anteriority</condition>
  <condition>Unexplained Hypophosphatemia</condition>
  <arm_group>
    <arm_group_label>Unexplained hypophosphatemia</arm_group_label>
    <description>Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>unexplained hypophoshatemia</intervention_name>
    <description>Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.</description>
    <arm_group_label>Unexplained hypophosphatemia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Major patient, male or female with hypophosphatemia (&lt; 0.80 mmol/L), without immediate&#xD;
        anteriority&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient, male or female&#xD;
&#xD;
          -  Taken care of at the Clermont-Ferrand University Hospital or the Jean Perrin Centre&#xD;
&#xD;
          -  In a context of hypophosphatemia (&lt; 0.80 mmol/L), without immediate anteriority and&#xD;
             not occurring during hospitalisation&#xD;
&#xD;
          -  In capacity to express informed consent to participate in research&#xD;
&#xD;
          -  Affiliated to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously diagnosed hypophosphatemia&#xD;
&#xD;
          -  Hypophosphatemia during hospitalisation&#xD;
&#xD;
          -  Haemodialysis patient&#xD;
&#xD;
          -  Refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damien BOUVIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>334.73.754.963</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre</last_name>
    </contact>
    <investigator>
      <last_name>Damien Bouvier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>lise Laclautre</last_name>
    </contact>
    <investigator>
      <last_name>Marie Batisse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Suvannasankha A, Tompkins DR, Edwards DF, Petyaykina KV, Crean CD, Fournier PG, Parker JM, Sandusky GE, Ichikawa S, Imel EA, Chirgwin JM. FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget. 2015 Aug 14;6(23):19647-60.</citation>
    <PMID>25944690</PMID>
  </reference>
  <reference>
    <citation>Imel EA, Biggin A, Schindeler A, Munns CF. FGF23, Hypophosphatemia, and Emerging Treatments. JBMR Plus. 2019 May 13;3(8):e10190. doi: 10.1002/jbm4.10190. eCollection 2019 Aug. Review.</citation>
    <PMID>31485552</PMID>
  </reference>
  <reference>
    <citation>Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, Yamauchi M, Sugimoto T, Minagawa M, Michigami T, Nagai M, Matsumoto T. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J. 2015;62(9):811-6. doi: 10.1507/endocrj.EJ15-0275. Epub 2015 Jul 1.</citation>
    <PMID>26135520</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FGF-23</keyword>
  <keyword>Unexplained hypophosphatemia</keyword>
  <keyword>Phosphate metabolism</keyword>
  <keyword>Physiopathology of hypophosphatemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypophosphatemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

